{"nctId":"NCT02671500","briefTitle":"Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV","startDateStruct":{"date":"2016-04-19","type":"ACTUAL"},"conditions":["Hepatitis C Virus Infection"],"count":375,"armGroups":[{"label":"SOF/VEL","type":"EXPERIMENTAL","interventionNames":["Drug: SOF/VEL"]}],"interventions":[{"name":"SOF/VEL","otherNames":["GS-7977/GS-5816","Epclusa®"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Willing and able to provide written informed consent\n* HCV RNA ≥ 10\\^4 IU/mL at screening\n* Chronic HCV infection (≥ 6 months) documented by prior medical history or liver biopsy\n* Any HCV genotype (1, 2, 3, 4, 5, 6 or indeterminate)\n* HCV treatment-naive or treatment-experienced\n* Liver imaging within 6 months of Day 1 is required in cirrhotic patients only to exclude hepatocellular carcinoma (HCC)\n\nKey Exclusion Criteria:\n\n* Current or prior history of clinically-significant illness (other than HCV), gastrointestinal disorder, clinical hepatic decompensation, or post-operative condition that could interfere with the absorption of the study drug\n* Pregnant or nursing female or male with pregnant female partner\n* Chronic liver disease of a non HCV etiology\n* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.5","spread":null},{"groupId":"OG001","value":"96.2","spread":null},{"groupId":"OG002","value":"97.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)","description":"SVR4 was defined as HCV RNA \\< LLOQ at 4 weeks after stopping study treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)","description":"SVR 24 was defined as HCV RNA \\< LLOQ at 24 weeks after stopping study treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ On Treatment","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.38","spread":"0.705"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.89","spread":"0.822"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.02","spread":"0.849"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.03","spread":"0.857"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.03","spread":"0.857"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.03","spread":"0.857"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.03","spread":"0.857"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Overall Virologic Failure","description":"Virologic failure was defined as: (1) On-treatment virologic failure: Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ while on treatment), or rebound (confirmed \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment) or (2) Virologic relapse: confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at last on-treatment visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":375},"commonTop":["Upper respiratory tract infection"]}}}